BSE: 0 | NSE: DHTL | Educational Institutions | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Docmode Health Technologies Ltd is a below average quality company.
The key valuation ratios of Docmode Health Technologies Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Docmode Health Technologies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 55% | 48.5% | 42% | 12.7% | - |
| Value Creation Index ⓘ | 2.9 | 2.5 | 2.0 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 7.1 | 12.4 | 32.9 | 40 | 40 |
| Sales YoY Gr. | - | 74.9% | 164.7% | 21.7% | - |
| Adj EPS ⓘ | 3.2 | 5.3 | 8.5 | 0.6 | 0.6 |
| YoY Gr. | - | 67% | 61.6% | -92.7% | - |
| BVPS (₹) ⓘ | 2.7 | 7.9 | 15.2 | 33 | 33 |
| Adj Net Profit ⓘ | 0.6 | 0.9 | 2 | 0.2 | 0 |
| Cash Flow from Ops. ⓘ | -0.5 | -2.1 | -0.8 | 4.5 | - |
| Debt/CF from Ops. ⓘ | -2.1 | -2.4 | -10.2 | 2.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 78% | 21.7% | ||||
| Adj EPS ⓘ | NA | NA | -41.8% | -92.7% | ||||
| BVPSⓘ | NA | NA | 131.9% | 117.8% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 118.9 | 99.5 | 80 | 2.8 | 1.9 |
| Op. Profit Mgn % ⓘ | 12.2 | 15.2 | 11.4 | 4.7 | NAN |
| Net Profit Mgn % ⓘ | 7.8 | 7.4 | 5.9 | 0.5 | 0.5 |
| Debt to Equity ⓘ | 2.3 | 3.5 | 2.4 | 0.9 | - |
| Working Cap Days ⓘ | 0 | 194 | 118 | 118 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 20 | -13 | 17 | 0 |
Sales growth is growing at healthy rate in last 3 years 77.95%
Debt to equity has declined versus last 3 years average to 0.88
Return on Equity has declined versus last 3 years average to 1.90%
Net Profit has been subdued in last 3 years -41.83%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.6 | 0.6 |
| TTM Sales (₹ Cr.) | 40 | 40 |
| BVPS (₹.) ⓘ | 33 | 33 |
| Reserves (₹ Cr.) ⓘ | 7 | 7 |
| P/BV ⓘ | 3.15 | 3.15 |
| PE ⓘ | 168.40 | 173.77 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 32.7 |
| Equity (₹ Cr.) | 3.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 42.8 |
| Pledged * | 0.00 | 0.00 | 61.16 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 7.10 | 12.42 | 32.88 | 40.01 |
| Operating Expenses ⓘ | 6.23 | 10.54 | 29.13 | 38.12 |
| Manufacturing Costs | 0.25 | 0.04 | 1.06 | 5.14 |
| Material Costs | 1.79 | 1.55 | 0.92 | 2.89 |
| Employee Cost | 1.62 | 4.29 | 5.56 | 4.95 |
| Other Costs ⓘ | 2.58 | 4.65 | 21.60 | 25.15 |
| Operating Profit ⓘ | 0.87 | 1.89 | 3.75 | 1.89 |
| Operating Profit Margin (%) | 12.2% | 15.2% | 11.4% | 4.7% |
| Other Income ⓘ | 0 | 0.01 | 0.10 | 0.14 |
| Interest ⓘ | 0.19 | 0.38 | 1.13 | 1.65 |
| Depreciation ⓘ | 0.04 | 0.02 | 0.02 | 0.02 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.65 | 1.50 | 2.69 | 0.35 |
| Tax ⓘ | 0.09 | 0.58 | 0.74 | 0.15 |
| Profit After Tax | 0.55 | 0.92 | 1.95 | 0.19 |
| PAT Margin (%) | 7.8% | 7.4% | 5.9% | 0.5% |
| Adjusted EPS (₹) | 3.2 | 5.3 | 8.5 | 0.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0.47 | 1.39 | 3.48 | 10.38 | ||||||
| Share Capital ⓘ | 0.01 | 0.01 | 2.29 | 3.14 | ||||||
| Reserves ⓘ | 0.46 | 1.38 | 1.19 | 7.24 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 0.66 | 3.51 | 5.66 | 5.48 | ||||||
| Long Term Debt | 0.66 | 3.37 | 4.42 | 4.38 | ||||||
| Short Term Debt | 0 | 0.15 | 1.25 | 1.10 | ||||||
| Trade Payables | 2.51 | 1.61 | 3.01 | 2.82 | ||||||
| Others Liabilities ⓘ | 1.99 | 3.50 | 4.72 | 7.75 | ||||||
| Total Liabilities ⓘ | 5.63 | 10.02 | 16.87 | 26.43 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 0.12 | 0.17 | 0.18 | 1.13 | ||||||
| Accumulated Depreciation | 0.09 | 0.11 | 0.14 | 0.16 | ||||||
| Net Fixed Assetsⓘ | 0.03 | 0.06 | 0.05 | 0.97 | ||||||
| CWIP ⓘ | 0.12 | 0.44 | 2.03 | 8.50 | ||||||
| Investmentsⓘ | 0.10 | 1.25 | 1.20 | 1.26 | ||||||
| Inventories | 3.28 | 2.50 | 2.53 | 2.51 | ||||||
| Trade Receivables | 1.36 | 3.82 | 8.29 | 7.91 | ||||||
| Cash Equivalents | 0.31 | 0.14 | 0.39 | 3.09 | ||||||
| Others Assetsⓘ | 0.43 | 1.81 | 2.38 | 2.19 | ||||||
| Total Assets ⓘ | 5.63 | 10.02 | 16.87 | 26.43 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -0.50 | -2.05 | -0.83 | 4.49 |
| PBT ⓘ | 0.65 | 1.50 | 2.69 | 0.35 |
| Adjustment ⓘ | 0.38 | 0.63 | 1.26 | 1.85 |
| Changes in Working Capital ⓘ | -1.52 | -4.08 | -4.79 | 2.29 |
| Tax Paid ⓘ | 0 | -0.10 | 0.01 | 0.01 |
| Cash Flow From Investing Activity ⓘ | -0.13 | -1.52 | -1.57 | -7.55 |
| Capex | -0.04 | -0.37 | -1.60 | -7.42 |
| Net Investments | -0.10 | -1.16 | 0.05 | -0.06 |
| Others ⓘ | 0 | 0 | -0.03 | -0.07 |
| Cash Flow From Financing Activityⓘ | 0.84 | 3.41 | 2.65 | 5.76 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0.14 | 6.71 |
| Net Proceeds from Borrowing ⓘ | 0.64 | 2.71 | 1.05 | -0.03 |
| Interest Paid ⓘ | -0.19 | -0.38 | -1.13 | -1.65 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 0.40 | 1.07 | 2.59 | 0.73 |
| Net Cash Flow ⓘ | 0.21 | -0.17 | 0.25 | 2.70 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 118.89 | 99.5 | 80.03 | 2.79 | ||||||
| ROCE (%) | 55.01 | 48.45 | 42.01 | 12.68 | ||||||
| Asset Turnover Ratio | 1.26 | 1.59 | 2.45 | 1.85 | ||||||
| PAT to CFO Conversion(x) | -0.91 | -2.23 | -0.43 | 23.63 | Working Capital Days | |||||
| Receivable Days | 70 | 76 | 67 | 74 | ||||||
| Inventory Days | 168 | 85 | 28 | 23 | ||||||
| Payable Days | 513 | 484 | 918 | 368 | ||||||
Docmode Health Technologies Limited was originally incorporated as a Private Limited Company in name and style of Docmode Health Technologies Private Limited under the provisions of Companies Act, 2013 vide Certificate of Incorporation dated July 17, 2017 issued by Assistant Registrar of Companies, Maharashtra, Mumbai. Subsequently, the Company was converted into a Public Limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on December 15, 2022 and consequent upon conversion the name of the company was changed to Docmode Health Technologies Limited vide a fresh certificate of incorporation dated January 2, 2023 issued by Assistant Registrar of Companies, Maharashtra, Mumbai.
The company is engaged in the business of offering integrated learning solutions through online and offline learning model to health care professionals and learners across the world, spanning the education value chain. The company’s offline learning model comprises of conferences and workshops. The company’s online courses content is reviewed and presented by its dedicated in-house content development team or by medical institution and medical associations (medical professional bodies) and subject matter experts/key opinion leaders who are focused to effectively transfer knowledge, as well as communicate and network with each other through its learning and professional networking platform.
The company mainly focuses on providing learning solutions through online model. Its tech based online learning model allows health care professionals and learners to engage in self-paced inclusive and individualized learning experience without the requirements of physical classroom present. The company’s online learning model comprises notes, recorded videos, live conferences, workshops etc. In addition to the learning solutions, the company provides a platform for inter-professional cross industrial learning via panel discussion and courses as well as takes advantage of its performance assessment tools to better their clinical acumen in their daily medical practice.
Business area of the company
The company is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry for the healthcare stakeholders. The company also conducts offline/ online events/ sessions/ seminars for knowledge enhancement and sharing for the healthcare stakeholders.
Services of the company
Awards, achievements and accolades
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
